| Item Type |
Article |
| ID |
|
| Preview |
| Image |
|
| Caption |
|
|
| Full text |
KAKEN_24791718seika.pdf
| Type |
:application/pdf |
Download
|
| Size |
:242.5 KB
|
| Last updated |
:Apr 11, 2016 |
| Downloads |
: 855 |
Total downloads since Apr 11, 2016 : 855
|
|
| Release Date |
|
| Title |
| Title |
子宮体癌におけるmiRNA治療薬の開発および診断への応用
|
| Kana |
シキュウタイガン ニ オケル miRNA チリョウヤク ノ カイハツ オヨビ シンダン エノ オウヨウ
|
| Romanization |
Shikyutaigan ni okeru miRNA chiryoyaku no kaihatsu oyobi shindan eno oyo
|
|
| Other Title |
| Title |
Application to the development and diagnosis of miRNA therapeutic agent in endometrial cancer
|
| Kana |
|
| Romanization |
|
|
| Creator |
| Name |
矢野倉, 恵
|
| Kana |
ヤノクラ, メグミ
|
| Romanization |
Yanokura, Megumi
|
| Affiliation |
慶應義塾大学・医学部・特任助教
|
| Affiliation (Translated) |
|
| Role |
Research team head
|
| Link |
科研費研究者番号 : 20433732
|
|
| Edition |
|
| Place |
|
| Publisher |
|
| Date |
| Issued (from:yyyy) |
2015
|
| Issued (to:yyyy) |
|
| Created (yyyy-mm-dd) |
|
| Updated (yyyy-mm-dd) |
|
| Captured (yyyy-mm-dd) |
|
|
| Physical description |
|
| Source Title |
| Name |
科学研究費補助金研究成果報告書
|
| Name (Translated) |
|
| Volume |
|
| Issue |
|
| Year |
2014
|
| Month |
|
| Start page |
|
| End page |
|
|
| ISSN |
|
| ISBN |
|
| DOI |
|
| URI |
|
| JaLCDOI |
|
| NII Article ID |
|
| Ichushi ID |
|
| Other ID |
|
| Doctoral dissertation |
| Dissertation Number |
|
| Date of granted |
|
| Degree name |
|
| Degree grantor |
|
|
| Abstract |
microRNAは, 癌の発症・進展・薬剤耐性とも大きく関わることが明らかになっている。我々は, 子宮体癌においてエピジェネティックに発現抑制される癌抑制型microRNAとしてmiR-34bを同定し, さらにmiR-34bと抗癌剤の併用による抗腫瘍効果を検討した。
3種の子宮体癌細胞株に対しパクリタキセルを作用させた時は, 全ての細胞株においてmiR-34b添加時に細胞生存率の低下が認められた。また, HEC-1Bをヌードマウスの皮下に移植後, 28日目にはパクリタキセル+miR-34b群は他の群に比し有意に腫瘍径の縮小が認められた(P<0.05)。
microRNAs have key roles in the onset, development and drug resistance of cancer. We identified miR-34b as a tumor suppressor-type microRNA with expression that is epigenetically suppressed in endometrial cancer. In this study, the antitumor effect of combined miR-34b and antitumor drugs on endometrial cancer was examined. [Results] There was no change in cell viability after administration of miR-34b following application of cisplatin or adriamycin to HEC-108, HEC-1B and KLE cells. However, after treatment with paclitaxel, cell viability after administration of miR-34b decreased in all three cell lines. Tumor development occurred 14 days after transplantation of HEC-1B cells in nude mice. Drugs were administered on that day and thereafter. The tumor diameter significantly decreased in mice treated with paclitaxel + miR-34b compared with the results for other treatments (P<0.05). The GFP fluorescence signal also markedly decreased after treatment with paclitaxel + miR-34b.
|
|
| Table of contents |
|
| Keyword |
|
| NDC |
|
| Note |
研究種目 : 若手研究(B)
研究期間 : 2012～2014
課題番号 : 24791718
研究分野 : 婦人科腫瘍学
|
|
| Language |
|
| Type of resource |
|
| Genre |
|
| Text version |
|
| Related DOI |
|
| Access conditions |
|
| Last modified date |
|
| Creation date |
|
| Registerd by |
|
| History |
|
| Index |
|
| Related to |
|
